News | Heart Valve Technology | April 06, 2018

University Hospitals Performs Ohio's First Transcatheter Mitral Valve Replacement

New APOLLO trial of Intrepid TMVR system offers alternative option for patients with severe mitral regurgitation

University Hospitals Performs Ohio's First Transcatheter Mitral Valve Replacement

April 6, 2018 —  University Hospitals Harrington Heart & Vascular Institute has officially opened the APOLLO trial, implanting the first Intrepid transcatheter mitral valve replacement system in the study. Alan Markowitz, M.D., and Guilherme F. Attizzani, M.D., performed the procedure, the first in the state of Ohio.

As part of the APOLLO trial, UH patients with severe symptomatic mitral regurgitation will have the opportunity to be randomized to receive either conventional open-heart mitral valve replacement surgery or an investigational transcatheter mitral valve replacement (TMVR). In addition, patients who are not good surgical candidates could have the opportunity of being treated with TMVR.

According to Attizzani, UH interventional cardiologist and co-director, Valve and Structural Heart Disease Center, UH Harrington Heart & Vascular Institute, the APOLLO trial is a welcome development for patients with mitral valve disease.

“There is currently no TMVR technology approved by the FDA [U.S. Food and Drug Administration] and this trial may open a new, very important avenue on the field,” said Attizzani, who is also assistant professor of medicine at Case Western Reserve University School of Medicine. “The only percutaneous technologies we currently have to treat mitral insufficiency are MitraClip, which enables percutaneous native mitral valve repair, and transcatheter valves used for valve-in-valve procedures. This study is, therefore, extremely important as it may lead to a paradigm shift in terms of the treatment of native mitral valve insufficiency.”

The APOLLO trial is testing the Intrepid TMVR system, which is compressed inside a hollow delivery catheter and is inserted between the ribs to enter the heart. The new replacement valve is expanded directly into the malfunctioning mitral valve. The outer stent frame is designed to attach and conform to the native valve without the need for additional sutures, tethers or anchors to secure the prosthesis. The inner stent houses the valve, which is made from bovine tissue and is intended to maintain blood flow.

The Intrepid valve is implanted using a transapical approach through the apex. However, the technology is expected to evolve and become even less invasive.

“Today, surgeons need to open a small hole in the apex of the heart, then the valve is advanced through it and implanted,” said Markowitz, chief surgical officer, and director, Valve and Structural Heart Disease Center, UH Harrington Heart & Vascular Institute, and clinical assistant professor of surgery, CWRU School of Medicine. “It’s a beating-heart procedure without the heart-lung machine. Industry is, however, already working on a technology that is going to be transseptal (i.e., can be done via puncture of the femoral vein). This will further reduce the invasion to the patient by not having to go through the apex.”

UH is the only healthcare system in Northeast Ohio to give its patients access to the APOLLO trial.

“In addition to the APOLLO trial, we offer MitraClip therapy, an FDA-approved therapy for mitral valve insufficiency,” said Markowitz. “We also perform valve-in-valve and other complex procedures. It’s the full spectrum of mitral valve interventions, a combined effort of interventional cardiology and cardiac surgery.”

Once the APOLLO trial is completed, Attizzani expects patients with mitral valve disease to have more options to treat mitral valve disorders.

“Although it is impossible to predict the trial results, my expectation is that the TMVR system will be shown to be safe and effective,” said Attizzani. “If it is demonstrated to be non-inferior to surgical mitral valve replacement, it will be a key step in terms of the potential future approval of this novel technology by the FDA, ultimately enabling more patients to have the option of an effective and less invasive procedure.”

For more information: www.medtronic.com

 


Related Content

News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
News | Heart Valve Technology

November 20, 2023 — Abbott announced new late-breaking data that show advanced heart failure patients living with its ...

Home November 20, 2023
Home
News | Heart Valve Technology

October 24, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announced that novel data from seven research studies ...

Home October 24, 2023
Home
News | Heart Valve Technology

October 17, 2023 — The Patel Children's Heart Institute at St. Joseph's Children's Hospital achieved a milestone ...

Home October 17, 2023
Home
Subscribe Now